ARQT Arcutis Biotherapeutics

Arcutis to Present at the 24th Annual Needham Virtual Healthcare Conference

Arcutis to Present at the 24th Annual Needham Virtual Healthcare Conference

WESTLAKE VILLAGE, Calif., March 27, 2025 (GLOBE NEWSWIRE) --  (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that Arcutis management will participate in the 24th Annual Needham Virtual Healthcare Conference, taking place April 7–10, 2025.

Details for the company’s participation are as follows:

        Fireside Chat Date: Tuesday, April 8, 2025

        Fireside Chat Time: 11:00 am EDT

The webcast for this conference may be accessed at the “” section of the Company’s website. A replay of the webcast will be available on the Arcutis website for 180 days following the conference.

About Arcutis

Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) is a commercial-stage medical dermatology company that champions meaningful innovation to address the urgent needs of individuals living with immune-mediated dermatological diseases and conditions. With a commitment to solving the most persistent patient challenges in dermatology, Arcutis has a growing portfolio including three FDA approved products that harness our unique dermatology development platform coupled with our dermatology expertise to build differentiated therapies against biologically validated targets. Arcutis’ dermatology development platform includes a robust pipeline with multiple clinical programs for a range of inflammatory dermatological conditions including scalp and body psoriasis, atopic dermatitis, and alopecia areata. For more information, visit  or follow Arcutis on , , and .

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. For example, statements contained in this press release regarding matters that are not historical facts are forward-looking statements. These statements are based on the Company’s current beliefs and expectations and are subject to substantial known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. Risks and uncertainties that may cause our actual results to differ include risks inherent in our business, reimbursement and access to our products, the impact of competition and other important factors discussed in the “Risk Factors” section of our Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) on February 25, 2025, as well as any subsequent filings with the SEC. Any forward-looking statements that the company makes in this press release are made pursuant to the Private Securities Litigation Reform Act of 1995, as amended, and speak only as of the date of this press release. Except as required by law, we undertake no obligation to revise or update information herein to reflect events or circumstances in the future, even if new information becomes available.

Contacts:

Media

Amanda Sheldon, Head of Corporate Communications

Investors

Latha Vairavan, Vice President, Finance and Corporate Controller



EN
27/03/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Arcutis Biotherapeutics

 PRESS RELEASE

Arcutis Announces Promotion of Mas Matsuda to Executive Vice President...

Arcutis Announces Promotion of Mas Matsuda to Executive Vice President and Chief Legal Officer to Support Next Phase of Growth WESTLAKE VILLAGE, Calif., March 05, 2026 (GLOBE NEWSWIRE) --  (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced the promotion of Mas Matsuda, JD, currently senior vice president and general counsel, to executive vice president, chief legal officer, and corporate secretary. Mr. Matsuda will continue to lead the Company’s legal, compliance, and governance strategy in suppo...

 PRESS RELEASE

Arcutis Begins Enrolling Phase 1a/1b Study Evaluating ARQ-234, a CD200...

Arcutis Begins Enrolling Phase 1a/1b Study Evaluating ARQ-234, a CD200R Agonist, in Healthy Volunteers and Adults With Atopic Dermatitis Phase 1a/1b, first-in-human study to evaluate safety and tolerability for investigational ARQ-234 in healthy volunteers and adults with moderate to severe atopic dermatitisARQ-234 is a potent fusion-protein agonist of the CD200 receptor (CD200R), an immune-regulatory checkpoint involved in maintaining immune balance WESTLAKE VILLAGE, Calif., March 03, 2026 (GLOBE NEWSWIRE) --  (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on devel...

 PRESS RELEASE

Arcutis Management to Present at TD Cowen’s 46th Annual Health Care Co...

Arcutis Management to Present at TD Cowen’s 46th Annual Health Care Conference WESTLAKE VILLAGE, Calif., Feb. 27, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that Arcutis management will present at the TD Cowen 46th Annual Health Care Conference, taking place March 2-4, 2026, in Boston. Details for the Company’s participation are as follows:     Fireside Chat: Monday, March 2, 2026 at 1:50 p.m. ET The webcast for this conference may be accessed via the “” sectio...

 PRESS RELEASE

Arcutis Announces Fourth Quarter and Full Year 2025 Financial Results ...

Arcutis Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update Q4 2025 net product revenue for ZORYVE® (roflumilast) was $127.5 million, an 84% increase compared to Q4 2024, and a 29% increase compared to Q3 2025Full year 2025 net product revenue for ZORYVE was $372.1 million, an increase of 123% over the prior yearReported positive topline data for the INTEGUMENT-INFANT Phase 2 trial of ZORYVE cream 0.05% in children ages 3 to 24 months with mild to moderate atopic dermatitis, with a Supplemental New Drug Application (sNDA) submission expected in Q2 2026...

 PRESS RELEASE

Professional Golfer Max Homa Joins Arcutis’ Free to Be Me Campaign, Ur...

Professional Golfer Max Homa Joins Arcutis’ Free to Be Me Campaign, Urging Individuals with Seborrheic Dermatitis to Tee Up a Conversation with Their Healthcare Provider About Long-Term Treatments Max Homa shares his journey with seborrheic dermatitis to encourage others to take control of their symptomsZORYVE® (roflumilast) foam 0.3% is a once-daily, steroid-free, leave-in topical foam uniquely formulated to treat the itching, redness, and flaking of seborrheic dermatitis anywhere it appears, including hair-bearing areas10 million Americans live with seborrheic dermatitis, a chronic inflam...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch